Media no image

Vironova is part of major effort to advance Sweden’s position in biological drugs

Press Releases   •   Jul 10, 2017 08:43 CEST

Biological drugs hold tremendous potential but are a major challenge to develop. New analytical methods will be needed, including transmission electron microscopy which Vironova is making accessible for the development and quality control processes in drug development.


“The product is the process.”

Biological structures are more complex to work with than regular small chemical drugs. For example, the finished product cannot be fully characterized. The manufacturing process itself must ensure product quality, and purity and needs to be monitored consistently with many analytical methods (such as Vironova’s MiniTEM system) to ensure predictable outcomes.

Vironova’s expertise makes us perfectly placed to participate in NextBioForm, a major effort to put Sweden in a leading position for development of biological drugs -  recently presented by Vinnova (Sweden's Innovation Authority) and the Swedish Research Council (Vetenskapsrådet).

NextBioForm is a collaboration and network forum where industry, academia, and healthcare providers join forces. Together with drug developers (SOBI, Ferring, Regenics, Spiber, BioGaia and Ilya Pharma) and other service and technology providers, (Solve, Waters and CR,) Vironova will contribute to helping shorten time-to-market of state-of-the-art biological drugs.

The NextBioForm centre is focussed on formulation and protein drugs while FormulaX,  which Vironova is also part of, focusses on RNA and nanoparticle-based distribution systems (lipid nanoparticles and exosomes).

For Vironova's part, it is important to develop methods and offerings to characterize biologics that the market wants and needs. Through NextBioForm we can participate in an international network of key actors to better understand the market. We also learn more about what the MiniTEM system can offer, and access early knowledge of emerging areas in the pharmaceutical sector.

The NextBioForm Centre receives 16 million SEK in the first stage. In total, there are 17 partners under the leadership of RISE and Centre Director Anna Fureby, anna.fureby@ri.se

For more information contact:

Ida-Maria Sintorn, Chief Technology Officer Vironova AB, +46 (0)76 1090195, ida.sintorn@vironova.com

Mohammed Homman, CEO, Vironova AB, +46 (0) 70 480 49 27, mohammed.homman@vironova.com

Vironova is a Swedish biotechnology company providing comprehensive, hardware, software and services for the analysis of nanoparticles. Vironova revolutionizes access to transmission electron microscopy (TEM)-based image analysis in biopharmaceutical development. Our solution enables automated analyses for faster and better- informed decisions to secure robust bioprocessing and final product quality.

The Vironova offering comprises:

  • Cost effective, fast Electron Microscopy (EM) services enabled by the in-house developed Vironova Analyzing Software (VAS) designed for semi-automated nanoparticle analysis
  • Viral clearance testing performed in GLP and BSLIII certified laboratories
  • MiniTEM™, a bench-top Transmission Electron Microscope system designed for automated nanoparticle characterization. High-resolution images reveal particle morphologies that are transformed into accurate metrics.

Vironova’s expertise makes us perfectly placed to participate in a major effort for development of biological drugs - recently presented by Vinnova and the Swedish Research Council. Biological structures are complex to work with; the manufacturing process must ensure product quality and needs to be monitored with many analytical methods such as Vironova’s MiniTEM system.

Read more »
Media no image

Vironova AB and AstraZeneca are partners in FoRmulaEx, a new Industrial Research Centre receiving 75Million SEK from SSF to work on key development bottlenecks for powerful new medicines

Press Releases   •   Jul 06, 2017 11:10 CEST

Vironova AB, AstraZeneca, Camurus AB and key research groups headed up by Chalmers University of technology, team up in the FoRmulaEx centre, a new multi-disciplinary Industrial Research Centre that has recently received funding of 75M SEK from the Swedish foundation for Strategic Research (SSF).

Complex, oligonucleotide drugs are the focus. Drugs like these, based on biological structures, are often superior to conventional small-molecule drugs and hold great future promise but it is a major challenge to get them to their targets inside cells. Drug delivery is a key bottleneck in their development.

The centre will develop methods for efficient and robust delivery of complex, oligonucleotide drugs. This requires the kind of advanced analytical methods with objective and reliable information tailored to pharmaceutical development that Vironova specializes in.

Vironova has a 10-year track record in providing expertise in electron microscopy and image analysis in a unique offering of hardware, software and services for nano-particle characterization tailored to the highly-regulated world of drug development. The solution includes compliance with Good Manufacturing Practice (GMP) that the pharmaceutical industry requires for the use of analytical methods in the whole process from research to batch release.

Vironova is the only actor to provide this comprehensive solution in an offering tailored to pharmaceutical regulatory systems.

“Vironova AB is truly privileged to be part of this powerful industrial research collaboration. Our participation is an endorsement of our unique, leading position in pharmaceutical electron microscopy and we are particularly excited to again be at the cutting edge of solving technology challenges in future healthcare.”

Mohammed Homman, CEO, Vironova AB

Partners:

Astra Zeneca provides industry expertise and infrastructure as well as expertise on oligonucleotide drugs.

Vironova AB will contribute by developing standardized methods for structural analysis of the drug delivery system developed within the centre.

Camurus AB is expert in lipid based drug delivery systems.

The team includes internationally recognized scientists at Chalmers, Karolinksa Institute and Gothenburg University, with Professor Fredrik Höök of Chalmers acting as coordinator.

See also:  http://nordiclifescience.org/two-new-swedish-industry-research-centres-with-life-science-focus/

For more information contact:

Mohammed Homman, CEO, Vironova AB, +46 (0) 70 480 49 27, mohammed.homman@vironova.com.

Josefina Nilsson, PhD, Head of Business Unit, EM Services, Vironova AB. +46 76 109 01 91.  Josefina.nilsson@vironova.com

Vironova is a Swedish biotechnology company providing comprehensive, hardware, software and services for the analysis of nanoparticles. Vironova revolutionizes access to transmission electron microscopy (TEM)-based image analysis in biopharmaceutical development. Our solution enables automated analyses for faster and better- informed decisions to secure robust bioprocessing and final product quality.

The Vironova offering comprises:

  • Cost effective, fast Electron Microscopy (EM) services enabled by the in-house developed Vironova Analyzing Software (VAS) designed for semi-automated nanoparticle analysis
  • Viral clearance testing performed in GLP and BSLIII certified laboratories
  • MiniTEM™, a bench-top Transmission Electron Microscope system designed for automated nanoparticle characterization. High-resolution images reveal particle morphologies that are transformed into accurate metrics.

As previously reported on www.vironova.com, Vironova AB, AstraZeneca, Camurus AB and key research groups headed up by Chalmers University of technology, have teamed up in the FoRmulaEx centre, a new multi-disciplinary Industrial Research Centre that has recently received funding of 75M SEK from the Swedish foundation for Strategic Research (SSF). The focus is on complex, oligonucleotide drugs.

Read more »
Media no image

Vironova awarded a key US patent for further automation of transmission electron microscopy

Press Releases   •   Apr 21, 2017 09:59 CEST

Vironova has recently been granted a US patent with the title " A method for automatic correction of astigmatism.” The method removes a tedious manual step that requires considerable operator skill. It can be applied to any electron microscope, allowing for automated correction of the electron beam and ultimately enabling fully automated image acquisition.

High quality image acquisition in electron microscopes requires careful alignment and focusing of the electron beam. A misaligned electron beam results in artefacts, a blurred image and loss of fine-detail information. Physical features and characteristics of the electron microscope can be used to coarsely perform the beam alignment. The fine-tuning is however conventionally left to manual adjustment by the user since wear of system parts, temperature etc. also affect the alignment and must be performed regularly.

Manual alignment of a transmission electron microscope (TEM) is a rather tedious, complicated and time-consuming process that requires very good operational skills.

An important feature of the present invention is that the method uses only image data to automatically correct for lens astigmatism during the alignment process, without relying on physical features and characteristics of the microscope itself. This means that the method can not only be used to perform the fine tuning but it can also be applied to any electron microscope, with no information required on internal physical features.

“This patent is a manifestation of our strategy to strengthen our core technology through a multi-disciplinary innovation process. Our constant goal is to increase user friendliness and improve the accessibility of the unique information inherent in electron microscopy.”  Mohammed Homman, CEO, Vironova AB.

“With this method we take an important step towards automatic, high quality image acquisition and ultimately fully automated and objective nano-particle characterization in life science and material science applications.”  Ida-Maria Sintorn, Chief Technology Officer Vironova AB.

For more information contact:

Ida-Maria Sintorn, Chief Technology Officer Vironova AB +46 (0)76 1090195, ida.sintorn@vironova.com

Founded in 2005 as a result of interdisciplinary research at the Karolinska Institute in Stockholm, Sweden, Vironova a company with 60 employees has quickly established a following of global customers working in highly-regulated and quality-demanding industries such as vaccine development, the pharmaceutical industry and material science. Vironova has developed a unique offering of services, hardware and software products. Today it has GLP-certified cell- and virus facilities that include equipment for advanced electron microscopy, image analysis, nano-characterization and viral clearance testing.

Vironova has recently been granted a US patent with the title " A method for automatic correction of astigmatism.” The method removes a tedious manual step that requires considerable operator skill. It can be applied to any electron microscope, allowing for automated correction of the electron beam and ultimately enabling fully automated image acquisition.

Read more »
Media no image

Record turnover for NOW Electronics in its first year as a Vironova-owned company

Press Releases   •   Mar 16, 2017 10:30 CET

A lot has happened at NOW Electronics since it became part of Vironova AB in December 2015. In August 2016, Mikael Wik was appointed as the new CEO. NOW’s founders, Per Neihoff and Henrik Wallin, who have together led NOW since 1985, continue to actively support the growth of NOW through sales and business development.

Together the new team has managed to beat all previous sales performance and deliver a turnover in 2016 of 25,9 MSEK, which is more than any other previous year.

“Acquisition of NOW is of great value in strengthening our technical edge, for example in developing the camera for MiniTEM and technical robustness of the system. We look forward to many more advances in the TEM technology and infrastructure.”  Mohammed Homman, CEO, Vironova.

NOW continues to grow, with a focus on new recruitments. The latest new addition to the team is a female with a degree in mechanics - particularly notable in this traditionally male-dominated sector.

Moving forward, the company will develop the current concept, focusing on profitable, long-term industrial projects but also exploring opportunities in the life science sector. At the same time NOW will maintain its in-house consulting with stimulating, technologically complexity projects that provide challenges, personal development and a feeling of community in the NOW team.

“It has been a truly exciting year for NOW and for myself in my new role as CEO. In a year of consolidation, new ownership and generation shift it’s very satisfying that our business has grown the way that it has. It tells us that we’re on the right track and the future looks promising.”  Mikael Wik, CEO, NOW Electronics

About NOW Electronics

NOW helps companies develop the software and electronics of tomorrow. In business since 1985 and owned by Vironova AB, NOW is situated in Kista, Stockholm. Highly experienced staff, a well-equipped electronics lab, modern tools for software development and a self-developed quality system allow NOW to develop products and systems that fulfil demanding customer requirements. NOW offers outsourcing as well as development in-house, consulting services, design inspections, system work and development of complete solutions. A close cooperation with subcontractors allows mass production of products in industry, military applications and medicine.  Read more here.

Contact:

Mikael Wik, CEO NOW Electronics, mikael.wik@now.se, +46 (0)70-377 36 68

Founded in 2005 as a result of interdisciplinary research at the Karolinska Institute in Stockholm, Sweden, Vironova a company with 60 employees has quickly established a following of global customers working in highly-regulated and quality-demanding industries such as vaccine development, the pharmaceutical industry and material science. Vironova has developed a unique offering of services, hardware and software products. Today it has GLP-certified cell- and virus facilities that include equipment for advanced electron microscopy, image analysis, nano-characterization and viral clearance testing.

NOW Electronics report record turnover of 25,9 MSEK in the first year as a Vironova-owned company. In 2016 Mikael Wik was appointed as CEO. The two founders and leaders since 1985 continue to be active in sales and business development. NOW continues to grow, with a focus on new recruitments, long-term projects and the life science sector. The core business of in-house consulting will continue.

Read more »
Media no image

Vironova AB is collaborating partner in Big Data and Computational Science project that received 29 M SEK in funding from the Swedish foundation for Strategic Research.

Press Releases   •   Feb 28, 2017 11:24 CET

Vironova AB is once again a proud participant in a cutting-edge research program. The Swedish foundation for Strategic Research (SSF) has announced 29 M SEK in funding for the project entitled “Hierarchical Analysis of Temporal and Spatial Image Data,” led by Uppsala University Professor Carolina Wählby. Other partners in the project are Astra Zeneca and SciLifeLab.

Vironova’s core expertise lies in electron microscopy. Microscopy imaging is one of the most powerful tools for investigation of complex biological processes, and automated analysis with high throughput techniques is capable of generating data at an unprecedented rate. But in the wake of all the advances during the last decade in digital image handling, a new bottleneck has arisen.

Images contain very rich information and the ever-increasing speed of data collection results in data-volumes that exceed available computational resources. Valuable information is often only a small part of the total data. Machine learning methods for analysis of massive image data are urgently needed, to avoid missing out on the promise of rapid advances in knowledge that this area holds.

Vironova recently launched the MiniTEM instrument, a compact transmission electron microscope (TEM) that makes the gold standard technique (TEM) for morphological analysis of nano-sized particles accessible in pharmaceutical development and quality control. It also opens the door for digital ultra-pathology (clinical ultrastructural pathology). The vast amount of search data a sample can yield in TEM presents a practical challenge that is addressed in multiple ways this proposal.

“Research collaborations, like this one in the area of big data, are the life blood of Vironova. The company has grown out of a multi-disciplinary research base in electron microscopy, digital imaging devices, software development and image analysis. We continue to nurture the scientific expertise and collaborations that are at the core of our strongest competitive advantage.”  Mohammed Homman, CEO, Vironova AB

The project is headed by Professor Carolina Wählby at Uppsala University Department of Information Technology and Vironova is represented by CTO Ida-Maria Sintorn who also holds the position as Associate Professor in computerized image processing at Uppsala University.

Contact:

Ida-Maria Sintorn, Chief Technology Officer Vironova AB +46 (0)76 1090195, ida.sintorn@vironova.com

Founded in 2005 as a result of interdisciplinary research at the Karolinska Institute in Stockholm, Sweden, Vironova a company with 60 employees has quickly established a following of global customers working in highly-regulated and quality-demanding industries such as vaccine development, the pharmaceutical industry and material science. Vironova has developed a unique offering of services, hardware and software products. Today it has GLP-certified cell- and virus facilities that include equipment for advanced electron microscopy, image analysis, nano-characterization and viral clearance testing.

Vironova AB is once again a proud participant in a cutting-edge research program. The Swedish foundation for Strategic Research (SSF) has announced 29 M SEK in funding for the project entitled “Hierarchical Analysis of Temporal and Spatial Image Data,” led by Uppsala University Professor Carolina Wählby. Other partners in the project are Astra Zeneca and SciLifeLab

Read more »
Media no image

Vironova AB signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS).

Press Releases   •   Feb 23, 2017 15:07 CET

In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body.

Proprietary Vironova Analyzing Software (VAS) in combination with Cryo-transmission electron microscopy (cryoTEM) enables semi-automated image analysis of liposomes, providing accurate, reproducible and timely results.

“Beta-testing is designed to help us accelerate development and improve the robustness and user friendliness of VAS. This is a very valuable compliment to the input from our internal microscopists who work with liposome characterization,” says Nina Ewerlöf, Head of Vironova instruments and software.

The U.S. Food and Drug Administration's National Center for Toxicological Research is a global resource for innovative scientific solutions in support of the agency’s mission to improve public health.

Founded in 2005 as a result of interdisciplinary research at the Karolinska Institute in Stockholm, Sweden, Vironova a company with 60 employees has quickly established a following of global customers working in highly-regulated and quality-demanding industries such as vaccine development, the pharmaceutical industry and material science. Vironova has developed a unique offering of services, hardware and software products. Today it has GLP-certified cell- and virus facilities that include equipment for advanced electron microscopy, image analysis, nano-characterization and viral clearance testing.

Vironova AB has signed an agreement with the U.S. Food and Drug Administration for beta-testing of the Vironova Analyzing Software (VAS). The testing will help accelerate development and improve robustness and user friendliness of VAS, which is used in combination with Cryo-transmission electron microscopy (cryoTEM) to enable semi-automated image analysis of liposomes.

Read more »
Iyq4lrsrlou9iywiyq8x

His Majesty Carl XVI Gustaf prize for remarkable entrepreneurial achievements to Mohammed Homman, founder and CEO of Vironova

News   •   Nov 03, 2016 17:52 CET

Twfu55ldumgf9a96refp

Great interest for the MiniTEM system at the Biotech Week in Boston October 4-7, 2016

Press Releases   •   Oct 12, 2016 11:07 CEST

The new MiniTEM low voltage transmission electron microscope system, specifically designed to characterize nanoparticles, was introduced for the first time to a larger audience at the Boston Biotech Week. The system combines Vironova’s advanced software for microscope control, automation and analysis with Delong Instrument’s low voltage technologies.

Eoatq9uvozffij0txoch

Ask the Expert editorial in Bioprocess International

Press Releases   •   Jul 04, 2016 13:19 CEST

The editorial article in the June issue of Bioprocess International describes how electron microscopy and image analysis performed by Vironova provide all the structural information needed for effective and high-quality research, development and manufacturing of gene and drug delivery systems.

Cwhq3roeyxkjfgqxp6o4

Vironovas dotterbolag NOW Electronics får ny VD

Press Releases   •   Jun 07, 2016 08:41 CEST

​Förvärvet av NOW Electronics AB som gjordes i december 2015 innebar en teknikförstärkning för Vironova och en fortsatt satsning på lösningar för elektronmikroskopbaserad teknologi. Mikael Wik tillträder i augusti som ny VD för NOW Electronics AB och bidrar förutom med sitt kunnande inom elektronikområdet även med sin passion och erfarenhet av affärsutveckling.

Contacts 2 contacts

Born 1974. Member of the Board since 2006. Mr. Homman has an M.Sc. in Chemistry and B.Sc in... Show more

About Vironova AB (publ)

World Leaders in Nano Characterization Technologies and Services

Founded in 2005 as a result of interdisciplinary research at the Karolinska Institute in Stockholm, Sweden, Vironova a company with 65 employees has quickly established a following of global customers working in highly-regulated and quality-demanding industries such as vaccine development, the pharmaceutical industry and material science. Vironova has developed a unique offering of services, hardware and software products. Today it has GLP-certified cell- and virus facilities that include equipment for advanced electron microscopy, image analysis, nano-characterization and viral clearance testing.

Address

  • Vironova AB (publ)
  • Gävlegatan 22
  • 113 30 Stockholm
  • Sweden
  • Our homepage

Investor Relations

Links